坦辛IIA针对细胞信号通路:癌症治疗的可信范式
Syed Sahajada Mahafujul Alam1, Arijit Samanta1, Faizan Uddin2
1Applied Biochemistry Laboratory, Department of Biological Sciences, Aliah University, Kolkata, 700160, India.
Pharmacological reports : PR
|July 13, 2023
概括
坦辛IIA (Tan IIA),是一种来自Salvia miltiorrhiza的天然化合物,通过抑制瘤生长和诱导细胞死亡,表现出强大的抗癌作用. 本综述探讨了它对抗各种癌症的机制.
科学领域:
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
- 在瘤学瘤学.
背景情况:
- 来自植物的天然化合物在传统医学中对于治疗包括癌症在内的疾病至关重要.
- 坦辛IIA (Tan IIA) 是一种主要的生物活性分子,来自Salvia miltiorrhiza,一种在中国传统医学 (TCM) 中使用的草药.
- IIA具有显著的抗癌特性,通过多种分子机制起作用.
研究的目的:
- 审查Tanshinone IIA (Tan IIA) 在治疗各种人类癌症中的作用.
- 阐明Tan IIA抗癌活性背后的分子机制.
- 突出Tan IIA在瘤学中的治疗潜力.
主要方法:
- 关于Tanshinone IIA (Tan IIA) 和其抗癌作用的研究文献综述.
- 分析详细研究Tan IIA对癌细胞增殖,转移,入侵和血管生成的影响.
- 对研究Tan IIA对关键癌症相关信号通路的调节的研究进行了审查.
主要成果:
- 丹IIA证明了对乳腺,宫,结直肠,胃,肺和前列腺癌细胞系的广泛抗癌疗效.
- 机制包括瘤细胞生长的抑制,扩散,转移,入侵和血管生成.
- IIA诱导癌细胞的亡和自.
- 它调节关键信号通路,例如PI3K/Akt,JAK/STAT,IGF-1R和Bcl-2-Caspase通路.
结论:
- 坦辛IIA (Tan IIA) 是一种有前途的天然化合物,具有显著的抗癌潜力.
- 它的多方面的作用机制为其在癌症治疗中使用提供了坚实的基础.
- 对Tan IIA的进一步研究可能会导致新的癌症治疗策略.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Tumor Immunotherapy
567
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
567
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
TGF - β Signaling Pathway
7.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K


